» Articles » PMID: 35588691

Epigenetic Adjuvants: Durable Reprogramming of the Innate Immune System with Adjuvants

Overview
Publisher Elsevier
Date 2022 May 19
PMID 35588691
Authors
Affiliations
Soon will be listed here.
Abstract

Development of effective vaccines is a critical global health priority. Stimulating antigen-specific B and T cells to elicit long-lasting protection remains the central paradigm of vaccinology. Adjuvants are components that enhance vaccine immunogenicity by targeting specific innate immune receptors and pathways. Recent data highlight the capacity of adjuvants to induce durable epigenetic reprogramming of the innate immune system to engender heightened resistance against pathogens. This raises the prospect of developing epigenetic adjuvants that, in addition to stimulating robust T and B cell responses, convey broad protection against diverse pathogens by training the innate immune system. In this review, we discuss our emerging understanding of the various vaccines and adjuvants and their effects on durable reprogramming of the innate immune response, their putative mechanisms of action, and the promise and challenges of developing epigenetic adjuvants as a universal vaccine strategy.

Citing Articles

Harnessing adjuvant-induced epigenetic modulation for enhanced immunity in vaccines and cancer therapy.

Megdiche Y, Salerno-Goncalves R Front Immunol. 2025; 16:1547213.

PMID: 40040700 PMC: 11876029. DOI: 10.3389/fimmu.2025.1547213.


Infection-induced trained immunity: a twist in paradigm of innate host defense and generation of immunological memory.

Bahl A, Pandey S, Rakshit R, Kant S, Tripathi D Infect Immun. 2024; 93(1):e0047224.

PMID: 39655962 PMC: 11784091. DOI: 10.1128/iai.00472-24.


Respiratory infection- and asthma-prone, low vaccine responder children demonstrate distinct mononuclear cell DNA methylation pathways.

Martino D, Schultz N, Kaur R, van Haren S, Kresoje N, Hoch A Clin Epigenetics. 2024; 16(1):85.

PMID: 38961479 PMC: 11223352. DOI: 10.1186/s13148-024-01703-0.


Respiratory Infection- and Asthma-prone, Low Vaccine Responder Children Demonstrate Distinct Mononuclear Cell DNA Methylation Pathways.

Martino D, Schultz N, Kaur R, Haren S, Kresoje N, Hoch A Res Sq. 2024; .

PMID: 38645021 PMC: 11030504. DOI: 10.21203/rs.3.rs-4160354/v1.


Current Understanding of Bacillus Calmette-Guérin-Mediated Trained Immunity and Its Perspectives for Controlling Intracellular Infections.

de Araujo A, Mambelli F, Sanches R, Marinho F, Oliveira S Pathogens. 2023; 12(12).

PMID: 38133271 PMC: 10745672. DOI: 10.3390/pathogens12121386.


References
1.
Pulendran B, Arunachalam P, OHagan D . Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021; 20(6):454-475. PMC: 8023785. DOI: 10.1038/s41573-021-00163-y. View

2.
Owen A, Fults J, Patil N, Hernandez A, Bohannon J . TLR Agonists as Mediators of Trained Immunity: Mechanistic Insight and Immunotherapeutic Potential to Combat Infection. Front Immunol. 2021; 11:622614. PMC: 7930332. DOI: 10.3389/fimmu.2020.622614. View

3.
Burny W, Callegaro A, Bechtold V, Clement F, Delhaye S, Fissette L . Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans. Front Immunol. 2017; 8:943. PMC: 5557780. DOI: 10.3389/fimmu.2017.00943. View

4.
Arts R, Novakovic B, Ter Horst R, Carvalho A, Bekkering S, Lachmandas E . Glutaminolysis and Fumarate Accumulation Integrate Immunometabolic and Epigenetic Programs in Trained Immunity. Cell Metab. 2016; 24(6):807-819. PMC: 5742541. DOI: 10.1016/j.cmet.2016.10.008. View

5.
Walk J, de Bree L, Graumans W, Stoter R, van Gemert G, van de Vegte-Bolmer M . Outcomes of controlled human malaria infection after BCG vaccination. Nat Commun. 2019; 10(1):874. PMC: 6382772. DOI: 10.1038/s41467-019-08659-3. View